Eagle Pharmaceuticals Inc expected to post earnings of $1.05 a share - Earnings Preview

Eagle Pharmaceuticals

05/05/2023 19:32

* Eagle Pharmaceuticals Inc  EGRX.OQ   EGRX.O  is expected
to show
a fall in quarterly revenue when it reports  results on May 9. 
    * The Woodcliff Lake New Jersey-based  company is expected
to
report  a 45.4% decrease in revenue to $63.287 million from
$115.87 million a year ago, according to the mean estimate from
3 analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Eagle
Pharmaceuticals Inc
is for earnings of $1.05 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $32​, above​ its last closing price
of $28.37. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  0.57        0.83       1.10      Beat    32.5
 Sep. 30 2022  0.88        0.91       1.12      Beat    23.5
 Jun. 30 2022  3.32        3.36       1.56      Missed  -53.6​
 Mar. 31 2022  3.88        3.88       4.04      Beat    4
 ​​Dec.        0.96        0.94       0.85      Missed  -9.6
 31 2021                                                
 Sep. 30 2021  0.83        0.83       0.56      Missed  -32.8​
 Jun. 30 2021  0.75        0.80       0.93      Beat    16.3
 Mar. 31 2021  0.74        0.65       0.24      Missed  -63.1
 This summary was machine generated May 5 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated